192 related articles for article (PubMed ID: 32014820)
21. Elevated serum soluble CD14 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma.
Li N; Zhu Q; Yang C; Li F; Zhou Z; Lv Y; Sang J; Han Q; Liu Z
Tumour Biol; 2016 May; 37(5):6607-17. PubMed ID: 26643893
[TBL] [Abstract][Full Text] [Related]
22. Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma.
Çavuş B; Akyuz F; İliaz R; Akyuz U; Duranyıldız D; Serilmez M; Tekin D; Evirgen S; Karaca Ç; Demir K; Beşışık F; Kaymakoğlu S
Exp Oncol; 2020 Sep; 42(3):208-214. PubMed ID: 32996733
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
[TBL] [Abstract][Full Text] [Related]
24. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
25. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma.
Liu HH; Fang Y; Wang JW; Yuan XD; Fan YC; Gao S; Han LY; Wang K
Medicine (Baltimore); 2020 May; 99(20):e20326. PubMed ID: 32443384
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma.
Pandyarajan V; Govalan R; Yang JD
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418899
[TBL] [Abstract][Full Text] [Related]
27. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
28. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma.
Nabih MI; Aref WM; Fathy MM
Arab J Gastroenterol; 2014; 15(3-4):103-7. PubMed ID: 25249230
[TBL] [Abstract][Full Text] [Related]
29. Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria.
Lei Z; Li J; Wu D; Xia Y; Wang Q; Si A; Wang K; Wan X; Lau WY; Wu M; Shen F
JAMA Surg; 2016 Apr; 151(4):356-63. PubMed ID: 26579636
[TBL] [Abstract][Full Text] [Related]
30. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
31. Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma.
Guo W; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang M; Wang G; Chen WQ; Guo L; Lu RQ; Zhou CH; Zhang X; Shi YH; Qiu SJ; Pan BS; Cao Y; Zhou J; Yang XR; Fan J
Clin Cancer Res; 2018 May; 24(9):2203-2213. PubMed ID: 29374055
[No Abstract] [Full Text] [Related]
32. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma.
Chimparlee N; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Payungporn S; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(16):7211-7. PubMed ID: 26514514
[TBL] [Abstract][Full Text] [Related]
33. Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma.
Song C; Zhu J; Ge Z; Yu C; Tian T; Wang H; Han J; Shen H; Dai J; Lu J; Hu Z
Clin Gastroenterol Hepatol; 2019 May; 17(6):1204-1206. PubMed ID: 30114488
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha-fetoprotein assessment.
Tajiri H; Takano T; Tanaka H; Ushijima K; Inui A; Miyoshi Y; Ozono K; Abukawa D; Endo T; Brooks S; Tanaka Y
Cancer Med; 2016 Nov; 5(11):3102-3110. PubMed ID: 27748053
[TBL] [Abstract][Full Text] [Related]
35. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma.
Ge T; Shen Q; Wang N; Zhang Y; Ge Z; Chu W; Lv X; Zhao F; Zhao W; Fan J; Qin W
Med Oncol; 2015 Mar; 32(3):59. PubMed ID: 25652109
[TBL] [Abstract][Full Text] [Related]
37. Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.
Jin Y; Wong YS; Goh BKP; Chan CY; Cheow PC; Chow PKH; Lim TKH; Goh GBB; Krishnamoorthy TL; Kumar R; Ng TP; Chong SS; Tan HH; Chung AYF; Ooi LLPJ; Chang JPE; Tan CK; Lee CGL
Sci Rep; 2019 Jul; 9(1):10464. PubMed ID: 31320713
[TBL] [Abstract][Full Text] [Related]
38. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.
Li N; Zhou Z; Li F; Sang J; Han Q; Lv Y; Zhao W; Li C; Liu Z
Oncotarget; 2017 Jul; 8(28):46020-46033. PubMed ID: 28545019
[TBL] [Abstract][Full Text] [Related]
39. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
40. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
